tbuckley/cabot-search huggingface dataset:
Erratum: CATMoS: Collaborative Acute Toxicity Modeling Suite
Authors: Kamel Mansouri, Agnes Karmaus, Jeremy Fitzpatrick, Grace Patlewicz, Prachi Pradeep, Domenico Alberga, Nathalie Alepee, Timothy E.H. Allen, Dave Allen, Vinicius M. Alves, Carolina H. Andrade, Tyler R. Auernhammer, Davide Ballabio, Shannon Bell, Emilio Benfenati, Sudin Bhattacharya, Joyce V. Bastos, Stephen Boyd, J.B. Brown, Stephen J. Capuzzi, Yaroslav Chushak, Heather Ciallella, Alex M. Clark, Viviana Consonni, Pankaj R. Daga, Sean Ekins, Sherif Farag, Maxim Fedorov, Denis Fourches, Domenico Gadaleta, Feng Gao, Jeffery M. Gearhart, Garett Goh, Jonathan M. Goodman, Francesca Grisoni, Christopher M. Grulke, Thomas Hartung, Matthew Hirn, Pavel Karpov, Alexandru Korotcov, Giovanna J. Lavado, Michael Lawless, Xinhao Li, Thomas Luechtefeld, Filippo Lunghini, Giuseppe F. Mangiatordi, Gilles Marcou, Dan Marsh, Todd Martin, Andrea Mauri, Eugene N. Muratov, Glenn J. Myatt, Dac-Trung Nguyen, Orazio Nicolotti, Reine Note, Paritosh Pande, Amanda K. Parks, Tyler Peryea, Ahsan Polash, Robert Rallo, Alessandra Roncaglioni, Craig Rowlands, Patricia Ruiz, Daniel Russo, Ahmed Sayed, Risa Sayre, Timothy Sheils, Charles Siegel, Arthur C. Silva, Anton Simeonov, Sergey Sosnin, Noel Southall, Judy Strickland, Yun Tang, Brian Teppen, Igor V. Tetko, Dennis Thomas, Valery Tkachenko, Roberto Todeschini, Cosimo Toma, Ignacio Tripodi, Daniela Trisciuzzi, Alexander Tropsha, Alexandre Varnek, Kristijan Vukovic, Zhongyu Wang, Liguo Wang, Katrina M. Waters, Andrew J. Wedlake, Sanjeeva J. Wijeyesakere, Dan Wilson, Zijun Xiao, Hongbin Yang, Gergely Zahoranszky-Kohalmi, Alexey V. Zakharov, Fagen F. Zhang, Zhen Zhang, Tongan Zhao, Hao Zhu, Kimberley M. Zorn, Warren Casey, Nicole C. Kleinstreuer
Journal: Environmental Health Perspectives (2021)
Receptor-effector coupling by G proteins: implications for normal and abnormal signal transduction
Authors: A. M. Spiegel
Journal: Endocrine Reviews (1992)

THE ROLE of heterotrimeric guanine nucleotide binding proteins (G proteins) in signal transduction was first covered in Endocrine Reviews in 1981, when three distinct G proteins involved in visual transduction and regulation of cAMP formation were recognized (1). This topic was updated in Endocrine Reviews in 1989 by which time the number of mammalian G proteins identified had doubled, and their roles in regulation of various phospholipases and ion channels had been recognized (2). Barely 3 years later, the number of distinct mammalian G proteins recognized has again doubled, multiple G proteins have been identified in invertebrates, plants, and single-celled eukaryotes, and the number of cellular functions shown to be regulated by G proteins has increased correspondingly. Numerous excellent reviews covering various aspects of this topic have recently appeared (3–9), but given the rapidity of progress in this field, an update in Endocrine Reviews appears timely. This review summarizes recent progress in our understanding of G protein structure, function, and diversity. Particular emphasis is given to the problem of defining specificity in coupling of receptors to various G proteins, and the involvement of abnormal G proteins in human disease. Two related areas, that of G protein-coupled receptors (10) and of low molecular weight GTP-binding proteins such as the ras p21 protooncogenes (7, 11, 12), have also undergone an explosive increase in information. Detailed consideration of the structure, function, and diversity of both of these important classes of protein beyond the scope of this review, but selected areas will covered as they relate to the heterotrimeric G proteins themselves. Our citation of the extensive literature on G proteins is not comprehensive; instead, we have emphasized more recent references, and in some instances directed the reader to recent reviews for more detailed coverage of a particular area.
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).
Authors: Howard M. Sandler, Chen Hu, Seth A. Rosenthal, Oliver Sartor, Leonard G. Gomella, Mahul Amin, James Purdy, Jeff M. Michalski, Mark Garzotto, Nadeem Pervez, Alexander G. Balogh, George Rodrigues, Luis Souhami, M. Neil Reaume, Scott G. Williams, Raquibul Hannan, Eric M. Horwitz, Adam Raben, Rebecca Paulus, William U. Shipley
Journal: Journal of Clinical Oncology (2015)

LBA5002 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Saturday, May 30, 2015, and in the Annual Meeting Proceedings online supplement to the June 20, 2015, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Deceptive Lyme Disease Diagnosis Linked With Serious Infections
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Occupational injuries among working adolescents in New York State
Authors: R. Belville
Journal: JAMA (1993)

<h3>Objective.</h3> —To determine the number, distribution, determinants, and health consequences of occupational injuries among working adolescents in New York State. <h3>Design.</h3> —A retrospective, population-based analysis of New York State workers' compensation award data and the Annual Demographic File, a supplement to the US Bureau of the Census Current Population Survey. <h3>Participants.</h3> —Adolescents, aged 14 through 17 years, who received workers' compensation awards for occupational injury from 1980 through 1987. <h3>Main Outcome Measures.</h3> —(1) Numbers, types, and rates of occupational injuries in working adolescents by age, sex, industry, and occupation; (2) health consequences of injury, especially disability and death; and (3) secular trends in injury award rates. <h3>Results.</h3> —A total of 9656 adolescents were compensated for occupational injuries; 4201 compensated adolescents (43.5%) suffered permanent disability; 31 working adolescents died. The annual mean rate of compensated occupational injury was 28.2 per 10000 adolescent workers. Rates were higher in males than in females and ranged from 8.2 per 10000 in 14-year-old male workers to 46.8 per 10000 in 17-year-old male workers. Highest rates by industry were seen in manufacturing (49.0/10 000 adolescent workers) and agriculture (46.2/10 000). Unskilled labor was the most dangerous occupation (52.3/10 000). <h3>Conclusion.</h3> —Occupational injuries are a substantial and underrecognized contributor to the continuing epidemic of injury among adolescents. (<i>JAMA</i>. 1993;269:2754-2759)
Reply
Authors: Rishi P. Singh, Robert Lehmann, Joseph Martel, Kevin Jong, Ayala Pollack, Alexis Tsorbatzoglou, Giovanni Staurenghi, Guadalupe Cervantes-Coste Cervantes, Louis Alpern, Satish Modi, Liza Svoboda, Adeniyi Adewale, Glenn J. Jaffe
Journal: Ophthalmology (2017)
The California Excise Tax on Cigarettes: The Tobacco Industry Profits From This Too-Reply
Authors: Dileep G. Bal
Journal: JAMA (1993)

<h3>In Reply.</h3> —We thank Dr Parra-Medina and her colleagues for pointing out an aspect of the collection of the cigarette tax in California that we were not aware of. The 0.85% discount rate given to cigarette wholesalers to offset the cost of affixing the tax stamps on individual packs of cigarettes is mandated by state law. We agree that the 25 cents per pack tax increase brought by Proposition 99 should not have increased the per-pack monetary value of the discount. We will look for ways to correct this inequity.
Officials of the Association 1969-1970
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MISCELLANEOUS.
Journal: JAMA (1885)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)
Authors: H.N.N. Ip, I. Hwang, J. Kang, K.-P. Kim, J.H. Jeong, H.-M. Chang, B.-Y. Ryoo, C. Yoo
Journal: Annals of Oncology (2018)
Do drugs alter the course of rheumatoid arthritis?
Authors: H Bird, V Wnght
Journal: Annals of the Rheumatic Diseases (1982)

Do drugs alter the course of rheumatoid arthritis?*The proliferation of nonsteroidal anti-inflammatory agents (NSAIA) for the treatment of rheumatic dis- eases has been matched in recent years by a proliferation of drugs that are claimed to have a disease modifying action in rheumatoid arthritis.Early contenders for this claim (aurothiomalate, hydroxychloroquine, and D-penicillamine) were discovered by serendipity.The search for novel com- pounds that might have comparable therapeutic action without side effects requires a critical evalua- tion of assessments that might be of use in measuring disease modifying action, and some workers remain unconvinced that such claims are valid even for established drugs such as aurothiomalate.Against this background the 3rd Annual Day Con- ference on 'Growing points in the treatment of rheumatic diseases' was devoted to whether drugs might alter the course of rheumatoid arthritis and how we might show they do.It was held in Harrogate on 1 April 1982, organised by Dr Howard Bird, and attracted a multidisciplinary audience of almost 100.Biochemical, cellular, and immunological aspects Dr N. Hall (Bath) discussed biochemical assessments with particular reference to serum sulphydryl measurements.NSAIAs caused little change in serial sulphydryl reactions, though antirheumatoid drugs including clozic and levamisole and some drugs con- ventionally classified as NSAIAs (benoxaprofen and fenclofenac) caused an increase.By contrast cyclophosphamide, which slowed radiological progression, caused no change.It was postulated serum -SH groups might have a protective role against excess superoxide dismutase activity.The relevance of macrophage function in chronic inflam- mation was discussed by Dr W. Dawson (Lilly Research Centre, Windlesham).Indomethacin had no effect on antigen-dependant lymphocyte prolifer- ation, but D-penicillamine was active, albeit only at very high dose.Studies were in progress on anti- inflammatory compounds that might have anti- rheumatoid action.Dr R. Clague (Manchester) described his work with autoimmunity to native type II collagen in rheumatoid arthritis.Conventional second-line
Hypothalamic Syndromes
Authors: I. S. Wechsler
Journal: BMJ (1956)

My interest in clinical manifestations of coma dates back to the epidemics of encephalitis, then called lethargic, which accompanied and followed the world- wide epidemic of influenza after the first world war.Among the varied clinical expressions of the encephalitides was a peculiar type of coma then called vigil.It usually set in fairly acutely and persisted unaltered for days or weeks and even months, sometimes ending in death, at others in seeming recovery only to be fol- lowed in certain instances months or years later by a Parkinson syndrome.The coma differed from the usual type.The eyes were frequently open, the eyeballs wandered and gave the erroneous impression that the individual was in contact with his environment.He might turn his head from side to side as if in response to sounds which he evidently did not hear.There were no signs of paralysis of the limbs.Characteristic in many cases was such profuse perspiration, often oily, as to require frequent change of bedclothes.Calling the coma vigil was the usual way of giving classical names to conditions which escaped explanation, in the vain belief that to coin a word or phrase is to create a scientific fact.Case 1.-A few years after the acute epidemics had spent themselves a girl of 18 was admitted to the Montefiore Hospital with the complaint of obesity, of inversion of the sleep mechanism, and of grave sexual moral lapses.There was a history of acute encephalitis.Previously normal in her behaviour, she now began to show symptoms of nymphomania.She would immodestly accost men and overtly express uncontrollable sexual urge, entirely out of keeping with her previous moral and ethical behaviour.The diagnosis of pituitary obesity was made but never proved.The suspicion of a hypothalamic syndrome, which could now be entertained in retrospect, was not even considered at that time.All we knew then was that in the diencephalon there was a corpus Luysi and a mammillo-thalamic bundle of Vicq d'Azyr.Case 2.-Also in the early 1920's a man was admitted to the hospital with the main complaint of hypothermia.His temperature fell as low as 94°F. (34.40 C.) and persisted unchanged for several weeks.One day it rose to 990 F.(37.20 C.).The acute rise of 5°F. (2.80 C.), the local signs, and the leucocytosis led to the diagnosis of acute mastoiditis.A mastoidectomy was done, and the temperature fell back to 940 F. (34.40 C.) as he made a comparatively rapid recovery.He died some time afterwards.At post-mortem examination a middle-fossa tumour was found impinging on the interbrain area.Case 3.-At about the same time I saw a man at the Mount Sinai Hospital in the terminal stages of general
Cardiovascular Disease
Authors: Joel M. Gore
Journal: JAMA (1990)

The results of multiple clinical trials performed during the 1980s make it clear in 1990 that thrombolytic therapy should be considered for all patients with evolving myocardial infarction. The major trials that have been completed or that are in progress include the following: the Thrombolysis in Myocardial Infarction (TIMI) Trial Phase I published in 1985<sup>1</sup>found that tissue plasminogen activator (TPA) was superior to streptokinase in dissolving coronary artery thrombi. The AIMS study<sup>2</sup>reported that the recently Food and Drug Administration—approved thrombolytic agent anisoylated streptokinase plasminogen activator complex can be given as a bolus with reperfusion results similar to those achieved with streptokinase. The TIMI Trial Phase II A published in November 1988<sup>3</sup>showed that, contrary to prevailing views, there was no advantage to performing angioplasty immediately after thrombolytic therapy over performing the procedure 18 to 24 hours later. The Second International Study of Infarct Survival<sup>4</sup>
In This Issue
Journal: Journal of Clinical Investigation (2011)

CNS drug development in the blink of an eyeThe development of drugs for CNS indications is not an efficient process; only 8% of candidate drugs that enter clinical trials gain FDA approval.A key reason for this low success rate is a paucity of preclinical tests that accurately predict drug efficacy and detect unwanted side effects.In this issue (3528-3541), Cahill and colleagues report a new preclinical approach that they hope can be used alongside current strategies to guide more efficient drug development for CNS indications.Specifically, they show that a wide variety of psychoactive compounds - sedatives; antipsychotic, antidepressant, and antiseizure drugs; and drugs of abuse, such as cocaine, morphine, and phencyclidine - induce characteristic alterations in visual stimulus-induced and/or spontaneous eye movements in mice and that monitoring these changes can be used to rapidly and quantitatively assess the response of mice to these compounds.The broad utility of this approach was highlighted by the use of eye-movement analysis to assess the pharmacokinetics of CNS-active drugs, the blood-brain barrier penetration of CNS-active compounds, and the efficacy of a pharmacological treatment in a mouse model of schizophrenia.Eye-movement analysis was also used to monitor disease progression in a mouse model of the neurodegenerative condition Huntington disease (HD) and could therefore be used to assess the effectiveness of candidate HD therapeutics.
Bladder Endometriosis
Authors: Jiun-Hung Geng, Yung-Chin Lee
Journal: New England Journal of Medicine (2019)

A 38-year-old woman presented with a 6-month history of intermittent hematuria, dysuria, and pelvic pain. Imaging revealed a mass at the bladder dome. Partial cystectomy was performed, and a diagnosis of bladder endometriosis was made.
Reinforcements in the Pure Food Crusade
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Myocardial expression of HER2 and HER4 in anthracycline-pretreated breast cancer patients
Authors: S. Landt, H. Bühler, N. Vorsteher, K. Evers, B. Duvnjak, H. Adam, N. Bangemann, J. U. Blohmer, G. Schaller
Journal: Journal of Clinical Oncology (2004)

652
Vital Statistics of the United States 1949. Part I: Natality, Mortality, Marriage, Divorce, Morbidity, and Life Table Data for the United States. General Tables by Place of Occurrence with Supplemental Tables for Hawaii, Puerto Rico, Virgin Islands, and Alaska, Part II: Natality and Mortality Data for the United States Tabulated by Place of Residence.
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Abstract 4326: Epigenetic control of chromosome instability by STAT3 in gastric cancer
Authors: Yu Ming Chuang, Sheng-Jou Hung, Jiang Liang Chou, Wan-Hong Huang, Pearlly S. Yan, Tsunglin Liu, Michael W.Y. Chan
Journal: Cancer Research (2019)

Abstract Gastric cancer is one of the most common causes of cancer death worldwide. Aberrant activation of JAK/STAT3 signaling is frequently observed in gastric cancer and associated with cancer progression. Our previous studies demonstrated that several STAT3 targets and tumor suppressors such as NR4A3 and GATA6 are found to be epigenetically silenced by DNA methylation in gastric cancer. However, the role of aberrant JAK/STAT3 signaling in the epigenetic changes of downstream targets is not fully understood. In this study, by using Methylation EPIC array, we compared the global methylation changes in gastric cancer patient samples with different STAT3 activation level. In silico analysis was also performed to identify STAT3 binding sites in those differentially methylated loci. Hypermethylated loci which are functionally relate carcinogenesis and mediated by STAT3 expression were examined. Interestingly, SMARCAL1, which was involved in chromosome stability and alternative lengthening of telomeres was identified. Unexpectedly, differentially methylated region (DMR) was not occurred in the promoter, but enhancer region located in the CpG island shore. Additionally, we also found a transcription factor binding site, YY1, which was a methylation-sensitive enhancer-promoter regulator, in this DMR region. By using a statistic shuffling model, we found that STAT3 related methylation changes were significantly associated with H3K4me1 and H3K27me3 at that region. TCGA dataset also indicated that this DMR with dramatic changes was occurred in chromosome instability (CIN) subtype of gastric cancer, whereas the expression of SMARCAL1 was decreased in precancerous lesion in previous published data. Taken together, STAT3-related methylation changes may regulate the activity of enhancer and affect the expression of SMARCAL1, during gastric cancer progression. Citation Format: Yu Ming Chuang, Sheng-Jou Hung, Jiang Liang Chou, Wan-Hong Huang, Pearlly S. Yan, Tsunglin Liu, Michael W.Y. Chan. Epigenetic control of chromosome instability by STAT3 in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4326.